People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ionetix Corp | — | Pharmaceuticals | Series B | $76.5M | $103.5M | 2024 |
Michael Tarnok at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Tarnok on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Martin | 1 | 13 |
| Gregory Martin | 1 | 4 |
| Kevin Cameron | 1 | 3 |
| Nancy Hargreaves | 1 | 2 |
| David J. Martin | 1 | 2 |
| Douglas Boothe | 1 | 1 |
| Gregory Taxin | 1 | 1 |
| Phun Phieu | 1 | 1 |
| Michael Tarnock | 1 | 1 |
| Carrie Busch | 1 | 1 |
| GREGORY J. TAXIN | 1 | 1 |
| MICHAEL J. TARNOCK | 1 | 1 |
| GREGORY J. MARTIN | 1 | 1 |
| KEVIN J. CAMERON | 1 | 1 |
| CARRIE J. BUSCH | 1 | 1 |
| Anthony Stagnolia | 1 | 1 |
| David Eve | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.